Why KIDS rose 20.2% on Oct 28 2026: earnings and fda clearance

THE SESSION

• 09:30 ETOpened at $24.94, +4.7% on the previous close of $23.82
• 09:37 ETRegular-session low, $24.79
• 15:21 ETRegular-session high, $31.51
• 15:59 ETLast trade of the regular session, $30.80, +29.3% on the previous close of $23.82
• Volume: 1.7M shares in regular hours, 4K before the open

KIDS opened at $24.94, briefly fell to $24.79, then climbed through the session to TapeRank’s 11:25 ET mover reading at $28.62, up 20.2% on the day. TapeRank’s read tied the move to record third-quarter revenue, a raised full-year sales outlook, and FDA clearance for a new femur nail system, while noting that the earnings miss tempered but did not negate the reaction. The stock reached $31.51 at 15:21 ET and finished regular trading at $30.80, up 29.3% from the previous close, with no halts.

WRITTEN WED OCT 28 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

• 06:03 ETBTIG Maintains Buy on OrthoPediatrics, Raises Price Target to $30Benzinga
• TUE 17:59 ETOrthoPediatrics Q3 2026 Earnings Call TranscriptBenzinga
• TUE 16:15 ET8-K — Regulation FD Disclosure; Financial Statements and ExhibitsSEC 8-K
• TUE 16:11 ETOrthoPediatrics Obtains FDA 510(k) Clearance of PNP | Femur Retrograde Nail System; Co Announces Completion Of The First Procedures Using The SystemBenzinga
• TUE 16:08 ETOrthoPediatrics Raises FY2026 Sales Guidance from $265.000M-$269.000M to $270.000M-$273.000M vs $266.983M EstBenzinga
• TUE 16:07 ET8-K — Results of Operations and Financial Condition; Financial Statements and ExhibitsSEC 8-K